Table 4 Responses to survey questions regarding willingness to participate in clinical trials of various lengths and frequency of visits
From: Attitudes toward clinical trials across the Alzheimer’s disease spectrum
| Trial design elements | Diagnostic group | Likelihood of participation | ||
|---|---|---|---|---|
| Very unlikely (score = 1–2) | Neutral (score = 3–5) | Very likely (score = 6–7) | ||
| Annual visits | CN | 5 (13.5%) | 14 (37.8%) | 18 (48.7%) |
| MCI | 2 (6.3%) | 5 (15.6%) | 25 (78.1%) | |
| Dementia | 5 (22.7%) | 1 (4.6%) | 16 (72.7%) | |
| Monthly visits | CN | 13 (35.1%) | 16 (43.2%) | 8 (21.6%) |
| MCI | 3 (9.4%) | 14 (43.8%) | 15 (46.9%) | |
| Dementia | 6 (27.3%) | 4 (18.2%) | 12 (54.6%) | |
| Weekly visits | CN | 17 (45.9%) | 17 (45.9%) | 3 (8.1%) |
| MCI | 10 (31.3%) | 15 (46.9%) | 7 (21.9%) | |
| Dementia | 10 (45.5%) | 6 (27.3%) | 6 (27.3%) | |
| 1-year study | CN | 8 (21.6%) | 15 (40.5%) | 14 (37.8%) |
| MCI | 3 (9.4%) | 11 (34.4%) | 18 (56.3%) | |
| Dementia | 5 (22.7%) | 4 (18.2%) | 13 (59.1%) | |
| 2-year study | CN | 7 (20.0%) | 19 (54.3%) | 9 (25.7%) |
| MCI | 4 (13.8%) | 8 (27.6%) | 17 (58.6%) | |
| Dementia | 5 (25.0%) | 3 (15.0%) | 12 (60.0%) | |
| 5-year study | CN | 11 (30.6%) | 17 (47.2%) | 8 (22.2%) |
| MCI | 6 (18.8%) | 11 (34.4%) | 15 (46.9%) | |
| Dementia | 7 (31.8%) | 3 (13.6%) | 12 (54.6%) | |